US 11,959,919 B2
Predicting cancer progression
Sven Skog, Huddinge (SE); Staffan Eriksson, Lidingö (SE); Bernard Tribukait, Drottingholm (SE); and Qimin He, Huddinge (SE)
Assigned to AROCELL AB, Stockholm (SE)
Filed by AROCELL AB, Uppsala (SE)
Filed on Dec. 30, 2019, as Appl. No. 16/730,778.
Application 12/626,802 is a division of application No. 10/555,935, abandoned, previously published as PCT/SE2004/000750, filed on May 14, 2004.
Application 16/730,778 is a continuation of application No. 15/357,762, filed on Nov. 21, 2016, granted, now 10,551,385.
Application 15/357,762 is a continuation of application No. 12/626,802, filed on Nov. 27, 2009, abandoned.
Claims priority of provisional application 60/471,245, filed on May 16, 2003.
Prior Publication US 2020/0124608 A1, Apr. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01)
CPC G01N 33/57488 (2013.01) [G01N 2333/91215 (2013.01); G01N 2800/54 (2013.01)] 8 Claims
 
1. A method of selecting an adjuvant treatment for a subject diagnosed with a cancer disease and treating the subject with the selected adjuvant treatment, the method comprising the steps of:
contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a first blood serum sample taken from the subject before completion of a cancer treatment selected from the group consisting of surgery, radio therapy, chemotherapy and a combination thereof;
determining a first amount of antibody binding to the STK1 protein in the first blood serum sample;
correlating the first amount of antibody binding to a first concentration of STK1 protein in the first blood serum sample using a standard curve defining a correlation between an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1;
contacting the antibody with a second blood serum sample taken from the subject within one to six months after completion of the cancer treatment;
determining a second amount of antibody binding to the STK1 protein in the second blood serum sample;
correlating the second amount of antibody binding to a second concentration of STK1 protein in the second body fluid sample using the standard curve;
identifying the subject as having a high risk of future cancer relapse if the second concentration is equal to or higher than the first concentration and otherwise identifying the subject as having a low risk of future cancer relapse;
selecting an adjuvant treatment for the subject based on whether the subject is identified as having high risk or low risk of future cancer relapse; and
treating the subject with the selected adjuvant treatment.